Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2022; 13(3):869-876. doi:10.7150/jca.65145 This issue Cite

Research Paper

Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer

Song Ee Park1, Hee Sung Kim2✉, Eun-Jung Jung3, Ja Hee Suh3, Hyeyoung Min4, Kyong-Choun Chi5, Jong Won Kim5, Joong-Min Park5, In Gyu Hwang1✉

1. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
2. Department of Pathology, Chung-Ang University College of Medicine, Seoul, Korea.
3. Department of Pathology, National Medical Center, Seoul, Korea.
4. College of Pharmacy, Chung-Ang University, Seoul, Korea.
5. Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea.

✉ Corresponding authors: In Gyu Hwang, Division of Hemato-oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, 84 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea. Phone: +82-2-6299-1403; Fax:+82-2-6299-2114; E-mail: oncolog More

Citation:
Park SE, Kim HS, Jung EJ, Suh JH, Min H, Chi KC, Kim JW, Park JM, Hwang IG. Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer. J Cancer 2022; 13(3):869-876. doi:10.7150/jca.65145. https://www.jcancer.org/v13p0869.htm
Other styles

File import instruction

Abstract

Graphic abstract

Purpose: This study aimed to investigate the relationship between DNA damage response (DDR) related protein expression and clinical outcomes of patients with stage II and III gastric cancer undergoing gastrectomy.

Materials and Methods: From January 2005 to December 2017, 217 gastrectomized patients with stage II and III gastric cancer were analyzed for disease-free and overall survival (DFS and OS, respectively) based on their DDR expression status. We performed the immunohistochemical assessment of MLH1, MSH2, at-rich interaction domain 1 (ARID1A), poly adenosine diphosphate-ribose polymerase 1 (PARP-1), breast cancer susceptibility gene 1 (BRCA1), and ataxia-telangiectasia mutated (ATM) using formalin-fixed paraffin-embedded (FFPE) samples.

Results: Among the 217 patients studied, the most common DDR gene whose expression was suppressed was high PARP-1 (n = 120, 55.3%), followed by ATM (n = 62, 28.6%), ARID1A (n = 45, 20.7%), MLH1 (n = 33, 15.2%), BRCA1 (n = 25, 11.5%), and MSH2 (n = 9, 4.1%). The low-expression PARP-1 group exhibited a significantly shorter 5-year OS rate than the high-expression PARP-1 group (48.1% vs. 62.7%; HR 1.519, 95% CI = 1.011-2.283, P = 0.044). In the multivariate OS analysis, TNM stage (II vs. III) (HR = 5.172, P < 0.001), low PARP-1 expression (HR = 1.697, P = 0.013) and adjuvant chemotherapy (HR = 0.382, P < 0.001) were the only significant prognostic factors.

Conclusions: Low PARP-1 expression level could be an indicator of poor prognosis in gastrectomized patients with stage II and III gastric cancer.

Keywords: DNA damage response (DDR), Poly adenosine diphosphate-ribose polymerase 1 (PARP-1), Gastric cancer, Survival, Gastrectomy

Citation styles

APA
Park, S.E., Kim, H.S., Jung, E.J., Suh, J.H., Min, H., Chi, K.C., Kim, J.W., Park, J.M., Hwang, I.G. (2022). Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer. Journal of Cancer, 13(3), 869-876. https://doi.org/10.7150/jca.65145.

ACS
Park, S.E.; Kim, H.S.; Jung, E.J.; Suh, J.H.; Min, H.; Chi, K.C.; Kim, J.W.; Park, J.M.; Hwang, I.G. Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer. J. Cancer 2022, 13 (3), 869-876. DOI: 10.7150/jca.65145.

NLM
Park SE, Kim HS, Jung EJ, Suh JH, Min H, Chi KC, Kim JW, Park JM, Hwang IG. Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer. J Cancer 2022; 13(3):869-876. doi:10.7150/jca.65145. https://www.jcancer.org/v13p0869.htm

CSE
Park SE, Kim HS, Jung EJ, Suh JH, Min H, Chi KC, Kim JW, Park JM, Hwang IG. 2022. Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer. J Cancer. 13(3):869-876.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use